Literature DB >> 9521198

HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome.

S Sundaresan1, T Mohanakumar, M A Smith, E P Trulock, J Lynch, D Phelan, J D Cooper, G A Patterson.   

Abstract

BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the most common cause of morbidity and mortality after lung transplantation (LT). A retrospective analysis of clinical and immunologic variables were done to identify those that might predict the development of BOS.
METHODS: Of 112 LT performed over a 42-month interval, 94 survived at least 3 months and form the basis of this analysis. There was a minimum of 21 months follow-up. BOS was defined on the basis of declining spirometry (FEV1 <80% of baseline) and/or the presence of histologic obliterative bronchiolitis. All variables analyzed were subjected first to a univariate analysis; those variables appearing to carry significance were then subjected to a multivariate logistic regression analysis.
RESULTS: Univariate analysis revealed the following to be predictors of the development of BOS: age (the probability of developing BOS declined with advancing age); donor/recipient HLA-A locus mismatch, with actuarial freedom from BOS being significantly greater with no A-locus mismatches versus cases with one or two mismatches (P=0.031); and development of anti-HLA antibodies after transplantation (P=0.006 vs. recipients without detectable antibodies). In multivariate analysis, only HLA locus mismatch and development of anti-HLA antibodies were significant independent predictors of the development of BOS. The remaining clinical variables (gender, type of LT, indication for LT, graft ischemic time, use of cardiopulmonary bypass, cytomegalovirus) and immunologic variables (crossmatch, frequent early acute rejection) did not correlate with the development of BOS.
CONCLUSIONS: These data suggest that BOS is the result of an immune process, that differences at the HLA-A locus may play an important role in this process, and antibody-mediated injury may play a role in BOS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521198     DOI: 10.1097/00007890-199803150-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  44 in total

1.  Antibody-mediated rejection of a unilateral donor lung in bilateral living-donor lobar lung transplantation: report of a case.

Authors:  Fengshi Chen; Naomi Chibana; Akihiro Kanematsu; Shunji Takakura; Kimiko Yurugi; Rie Hishida; Atushi Fukatsu; Takeshi Kubo; Tsuyoshi Shoji; Takuji Fujinaga; Toru Bando; Hiroshi Date
Journal:  Surg Today       Date:  2012-02-28       Impact factor: 2.549

2.  Influence of HLA Mismatching on Survival in Lung Transplantation.

Authors:  Don Hayes; Bryan A Whitson; Samir N Ghadiali; Joseph D Tobias; Heidi M Mansour; Sylvester M Black
Journal:  Lung       Date:  2015-07-29       Impact factor: 2.584

3.  Inhibition of renin angiotensin aldosterone system causes abrogation of obliterative airways disease through inhibition of tumor necrosis factor-α-dependant interleukin-17.

Authors:  Joseph Weber; Venkataswarup Tiriveedhi; Masashi Takenaka; Wei Lu; Ramsey Hachem; Elbert Trulock; G Alec Patterson; T Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2012-01-29       Impact factor: 10.247

Review 4.  Molecular mechanisms of chronic rejection following transplantation.

Authors:  Elbert Kuo; Takahiro Maruyama; Felix Fernandez; T Mohanakumar
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  Mechanisms of chronic rejection in cardiothoracic transplantation.

Authors:  Matthew J Weiss; Joren C Madsen; Bruce R Rosengard; James S Allan
Journal:  Front Biosci       Date:  2008-01-01

Review 6.  Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies.

Authors:  Andrew I R Scott; Linda D Sharples; Susan Stewart
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Role of alloimmunity and autoimmunity in allograft rejection.

Authors:  Babak Banan; Zhongping Xu; Muthukumar Gunasekaran; T Mohanakumar
Journal:  Clin Transpl       Date:  2013

8.  Critical role for IL-17A/F in the immunopathogenesis of obliterative airway disease induced by Anti-MHC I antibodies.

Authors:  Haseeb Ilias Basha; Sabarinathan Ramachandran; Venkataswarup Tiriveedhi; Masashi Takenaka; Vijay Subramanian; Dilip S Nath; Nicholas Benshoff; G Alec Patterson; Thalachallour Mohanakumar
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

9.  The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.

Authors:  Xiaoqin Hua; Tobias Deuse; Yi-Je Chen; Heike Wulff; Mandy Stubbendorff; Ralf Köhler; Hiroto Miura; Florian Länger; Hermann Reichenspurner; Robert C Robbins; Sonja Schrepfer
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

10.  Tissue-associated self-antigens containing exosomes: Role in allograft rejection.

Authors:  Monal Sharma; Ranjithkumar Ravichandran; Sandhya Bansal; Ross M Bremner; Michael A Smith; T Mohanakumar
Journal:  Hum Immunol       Date:  2018-06-15       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.